Everist Genomics may be based in Ann Arbor but the medical device start-up sees a lot of its growth coming from overseas sales this year.
The 2-year-old company's principal technology, AngioDefender, helps doctors measure risk of strike and cardiovascular disease. Everist Genomics hopes to begin sales in the U.S. next year after it gets FDA approval. In the meantime, it has gotten approval to begin sales in Europe, India and Canada this year. The firm expects its exports to these foreign markets will create exponential growth.
"We believe the Canadian market will be really important to not only us but other medical device companies in Michigan because we're close to the border," says Randal Charlton, director of
Everist Genomics.
AngioDefender is a non-invasive diagnostic system that utilizes non-invasive sensor technology and a sophisticated software algorithm to help physicians diagnose ailments like cardiovascular disease in its early stages. The idea is that finding who is at greater risk of cardiovascular disease and stroke help medical professionals prevent heart attacks, strokes or high-blood pressure complications.
"We believe that could be a blockbuster product because it's non-invasive," Charlton says. "It tells you whether you're at risk of cardio-vascular disease or stroke."
Charlton, the former executive director of TechTown in Detroit, is using the technology himself and keeping a blog of it, which can be read
here.
Everist Genomics currently employs 30 people in Ann Arbor and another 10 overseas. It has hired three people over the last year, primarily in marketing, and is looking to hire another three.
"The growth in employees is about to take off in the next 6-to-12 months," Charlton says.
Source: Randal Charlton, director of Everist Genomics
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.